Literature DB >> 17525045

False-positive beta-human chorionic gonadotropin values in the follow-up of gestational trophoblastic disease.

V M Díaz Muñoz de la Espada1, J A Arranz Arija, P Khosravi Shahi, S Encinas García, R Alvarez Alvarez, R González Beca.   

Abstract

Gestational trophoblastic disease consists of a pathological spectrum of entities from molar pregnancies, which are premalignant conditions, to malignant invasive choriocarcinoma. Serum Beta-human chorionic gonadotropin (hCG) levels are essential both in the diagnosis and in the follow-up. There are high rates of complete responses and long-term survivors, because of the excellent chemosensitivity of these tumours. After initial management, an increased level of Beta-hCG indicates persistent disease. However, in the absence of evidence of persistent disease, false-positive Beta-hCG values may be considered. We present here the case of a woman with a metastatic choriocarcinoma in complete response after chemotherapy, who developed later persistent false-positive values of Beta-hCG in the follow-up. Causes of false-positive Beta-hCG determinations are revised.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525045     DOI: 10.1007/s12094-007-0062-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  12 in total

Review 1.  Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature.

Authors:  S J Steigrad; A P Cheung; R A Osborn
Journal:  J Obstet Gynaecol Res       Date:  1999-06       Impact factor: 1.730

2.  Discordant results in human chorionic gonadotropin assays.

Authors:  L A Cole; A Kardana
Journal:  Clin Chem       Date:  1992-02       Impact factor: 8.327

3.  Workshop Report: Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society.

Authors:  E. I. Kohorn; D. P. Goldstein; B. W. Hancock; S. J. Kim; J. R. Lurain; E. Newlands; J. T. Soper; L. C. Wong
Journal:  Int J Gynecol Cancer       Date:  2000-01       Impact factor: 3.437

4.  False-positive human chorionic gonadotropin levels caused by a heterophile antibody with the immunoradiometric assay.

Authors:  J H Check; K Nowroozi; J S Chase; C Lauer; B Elkins; C H Wu
Journal:  Am J Obstet Gynecol       Date:  1988-01       Impact factor: 8.661

5.  EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.

Authors:  M Bower; E S Newlands; L Holden; D Short; C Brock; G J Rustin; R H Begent; K D Bagshawe
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

6.  The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT).

Authors:  K D Bagshawe; J Dent; E S Newlands; R H Begent; G J Rustin
Journal:  Br J Obstet Gynaecol       Date:  1989-07

7.  Phantom hCG and phantom choriocarcinoma.

Authors:  L A Cole
Journal:  Gynecol Oncol       Date:  1998-11       Impact factor: 5.482

Review 8.  Detection of hCG in trophoblastic disease. The USA hCG reference service experience.

Authors:  Laurence A Cole; Stephen Butler
Journal:  J Reprod Med       Date:  2002-06       Impact factor: 0.142

Review 9.  False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition.

Authors:  Glenn D Braunstein
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

10.  Pulsatile secretion of human chorionic gonadotropin in normal adults.

Authors:  W D Odell; J Griffin
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.